Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.

Claire Dupuis, Ayman Sabra, Juliette Patrier, Gwendoline Chaize, Amine Saighi, Céline Féger, Alexandre Vainchtock, Jacques Gaillat, Jean-François Timsit
Author Information
  1. Claire Dupuis: AP-HP, Medical and Infectious Diseases Intensive Care Unit (MI2), Bichat-Claude Bernard University Hospital, 46 rue Henri Huchard, 75018, Paris, France.
  2. Ayman Sabra: Pfizer France, Paris, France.
  3. Juliette Patrier: AP-HP, Medical and Infectious Diseases Intensive Care Unit (MI2), Bichat-Claude Bernard University Hospital, 46 rue Henri Huchard, 75018, Paris, France.
  4. Gwendoline Chaize: HEVA, Lyon, France.
  5. Amine Saighi: Pfizer France, Paris, France.
  6. Céline Féger: EMIBiotech, Paris, France.
  7. Alexandre Vainchtock: HEVA, Lyon, France.
  8. Jacques Gaillat: Infectious Diseases Department, Annecy-Genevois Hospital, Annecy, France.
  9. Jean-François Timsit: AP-HP, Medical and Infectious Diseases Intensive Care Unit (MI2), Bichat-Claude Bernard University Hospital, 46 rue Henri Huchard, 75018, Paris, France. jean-francois.timsit@aphp.fr. ORCID

Abstract

BACKGROUND: Community-acquired pneumonia (CAP), especially pneumococcal CAP (P-CAP), is associated with a heavy burden of illness as evidenced by high rates of intensive care unit (ICU) admission, mortality, and costs. Although well-defined acutely, determinants influencing long-term burden are less known. This study assessed determinants of 28-day and 1-year mortality and costs among P-CAP patients admitted in ICUs.
METHODS: Data regarding all hospital and ICU stays in France in 2014 were extracted from the French healthcare administrative database. All patients admitted in the ICU with a pneumonia diagnosis were included, except those hospitalized for pneumonia within the previous 3 months. The pneumococcal etiology and comorbidities were captured. All hospital stays were included in the cost analysis. Comorbidities and other factors effect on the 28-day and 1-year mortality were assessed using a Cox regression model. Factors associated with increased costs were identified using log-linear regression models.
RESULTS: Among 182,858 patients hospitalized for CAP in France for 1 year, 10,587 (5.8%) had a P-CAP, among whom 1665 (15.7%) required ICU admission. The in-hospital mortality reached 22.8% at day 28 and 32.3% at 1 year. The mortality risk increased with age > 54 years, malignancies (hazard ratio (HR) 1.54, 95% CI [1.23-1.94], p = 0.0002), liver diseases (HR 2.08, 95% CI [1.61-2.69], p < 0.0001), and the illness severity at ICU admission. Compared with non-ICU-admitted patients, ICU survivors remained at higher risk of 1-year mortality. Within the following year, 38.2% (516/1350) of the 28-day survivors required at least another hospital stay, mostly for respiratory diseases. The mean cost of the initial stay was €19,008 for all patients and €11,637 for subsequent hospital stays within 1 year. One-year costs were influenced by age (lower in patients > 75 years old, p = 0.008), chronic cardiac (+ 11% [0.02-0.19], p = 0.019), and respiratory diseases (+ 11% [0.03-0.18], p = 0.006).
CONCLUSIONS: P-CAP in ICU-admitted patients was associated with a heavy burden of mortality and costs at one year. Older age was associated with both early and 1-year increased mortality. Malignant and chronic liver diseases were associated with increased mortality, whereas chronic cardiac failure and chronic respiratory disease with increased costs.
TRIAL REGISTRATION: N/A (study on existing database).

Keywords

References

  1. Intensive Care Med. 2018 Dec;44(12):2162-2173 [PMID: 30456466]
  2. Respir Med. 2018 Apr;137:6-13 [PMID: 29605214]
  3. Infection. 2018 Oct;46(5):669-677 [PMID: 29974388]
  4. Cardiovasc Diabetol. 2018 Apr 18;17(1):57 [PMID: 29669543]
  5. Chest. 2018 Feb;153(2):427-437 [PMID: 29017956]
  6. mBio. 2011 Jan 25;2(1):e00309-10 [PMID: 21264063]
  7. Expert Rev Anti Infect Ther. 2018 Sep;16(9):667-677 [PMID: 30118377]
  8. J Support Oncol. 2010 Jan-Feb;8(1):28-34 [PMID: 20235421]
  9. Health Serv Res Manag Epidemiol. 2020 Jul 24;7:2333392820939801 [PMID: 32782916]
  10. PLoS Med. 2011 Jun;8(6):e1001048 [PMID: 21738449]
  11. Am J Respir Crit Care Med. 2004 Apr 15;169(8):910-4 [PMID: 14693672]
  12. Medicine (Baltimore). 2008 Nov;87(6):329-334 [PMID: 19011504]
  13. Eur J Health Econ. 2018 May;19(4):533-544 [PMID: 28547724]
  14. PLoS One. 2016 Feb 05;11(2):e0148741 [PMID: 26849359]
  15. Crit Care Med. 2013 May;41(5):1229-36 [PMID: 23591209]
  16. Value Health. 2019 Nov;22(11):1329-1344 [PMID: 31708071]
  17. Vaccine. 2020 Jan 22;38(4):741-751 [PMID: 31843272]
  18. Curr Opin Pulm Med. 2016 May;22(3):212-8 [PMID: 26886878]
  19. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72 [PMID: 17278083]
  20. Expert Rev Respir Med. 2019 Feb;13(2):139-152 [PMID: 30596308]
  21. JAMA. 2018 Jan 2;319(1):62-75 [PMID: 29297082]
  22. N Engl J Med. 2015 Jul 2;373(1):93 [PMID: 26132952]
  23. Thorax. 2012 Jan;67(1):71-9 [PMID: 20729232]
  24. Aliment Pharmacol Ther. 2019 Jan;49(1):84-90 [PMID: 30485467]
  25. Curr Med Res Opin. 2020 Jan;36(1):151-160 [PMID: 31566005]
  26. Crit Care. 2018 Jan 18;22(1):8 [PMID: 29347987]
  27. Rev Invest Clin. 2016 Sep-Oct;68(5):221-228 [PMID: 27941957]
  28. Clin Infect Dis. 2003 Dec 15;37(12):1617-24 [PMID: 14689342]
  29. Am J Cardiol. 2015 Aug 15;116(4):647-51 [PMID: 26089009]
  30. Open Forum Infect Dis. 2019 Nov 30;6(12):ofz510 [PMID: 31868865]
  31. Crit Care Med. 2011 Aug;39(8):1886-95 [PMID: 21516036]
  32. Acta Anaesthesiol Scand. 2011 Nov;55(10):1254-60 [PMID: 22092131]
  33. Curr Opin Infect Dis. 2013 Apr;26(2):151-8 [PMID: 23426328]
  34. Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):785-791 [PMID: 30778705]
  35. Clin Infect Dis. 2008 Aug 1;47(3):375-84 [PMID: 18558884]
  36. MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075 [PMID: 31751323]
  37. BMC Infect Dis. 2016 Aug 03;16:367 [PMID: 27487784]
  38. Crit Care Med. 2010 Nov;38(11):2108-16 [PMID: 20802324]
  39. BMC Infect Dis. 2015 Jan 08;15:2 [PMID: 25566688]
  40. BMC Health Serv Res. 2017 Aug 17;17(1):572 [PMID: 28818082]

MeSH Term

Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Cost of Illness
Female
France
Health Care Costs
Hospital Bed Capacity
Hospital Mortality
Humans
Infant
Intensive Care Units
Length of Stay
Male
Middle Aged
Pneumonia, Pneumococcal
Retrospective Studies
Risk Factors
Severity of Illness Index

Word Cloud

Created with Highcharts 10.0.0mortalitycostsICUpneumoniapatientsassociated1-yearincreasedP-CAPadmissionhospitaldiseaseschronicCAPpneumococcalburden28-daystays1 yearrespiratoryCommunity-acquiredheavyillnesscareunitdeterminantsstudyassessedamongadmittedFrancedatabaseincludedhospitalizedwithincostComorbiditiesusingregression8%requiredriskHR95%CI[1p = 0liversurvivorsyearstay008agecardiac+ 11%[0BACKGROUND:especiallyevidencedhighratesintensiveAlthoughwell-definedacutelyinfluencinglong-termlessknownICUsMETHODS:Dataregarding2014extractedFrenchhealthcareadministrativediagnosisexceptprevious3 monthsetiologycomorbiditiescapturedanalysisfactorseffectCoxmodelFactorsidentifiedlog-linearmodelsRESULTS:Among1828581058751665157%in-hospitalreached22day28323%age > 54 yearsmalignancieshazardratio15423-194]000220861-269]p < 00001severityComparednon-ICU-admittedremainedhigherWithinfollowing382%516/1350leastanothermostlymeaninitial€19€11637subsequentOne-yearinfluencedlowerpatients > 75 yearsoldp = 002-019]01903-018]p =0006CONCLUSIONS:ICU-admittedoneOlderearlyMalignantwhereasfailurediseaseTRIALREGISTRATION:N/AexistingBurdenrequiringFrance:prognosisresourcesuseDirectIntensiveLong-termoutcomePneumococcalStreptococcuspneumoniae

Similar Articles

Cited By (12)